Relay Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.47B
- P/E (TTM)
- –
- Dividend yield
- –
About Relay Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Relay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates. The firm concentrates its efforts on precision oncology and genetically defined diseases through targeted therapies designed to address validated biological mechanisms. Rather than offering commercialized medical products, its clinical pipeline includes experimental drug programs and therapeutic opportunities being investigated for targeted patient groups.
The company operates primarily within the United States, managing its research and laboratory activities in Massachusetts. It maintains corporate headquarters, principal executive offices, and administrative facilities located in Cambridge, Massachusetts. Relay Therapeutics carries out its operations and ongoing clinical studies across selected domestic research sites, relying on agreements with external partners, clinical investigators, and institutions to advance its investigative development programs.
Summary of the business section of Relay Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Relay Therapeutics, Inc.
- Founded
- 2016
- Headquarters
- Cambridge, MA
- Address
- 60 Hampshire Street 02139
- Phone
- (617) 370-8837
- Website
- relaytx.com
- Employees
- 192, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RLAY
- Exchange
- Nasdaq
- IPO date
- Jul 16, 2020
- Shares outstanding
- 219M, Jul 31, 2026
- Public float
- $585.50M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1812364
- CUSIP
- 75943R102
- ISIN
- US75943R1023
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sanjiv Patel | President and CEO, Director | 1,406,403 |
| Donald A. Bergstrom | President, R&D | 399,130 |
| Thomas Catinazzo | Chief Financial Officer | 122,851 |
| Peter Rahmer | See remarks | 223,657 |
| Brian Adams | Chief Legal Officer | 371,472 |
| Alexis Borisy | Director | 234,175 |
| Mark Murcko | Director | 996,952 |
| Claire Mazumdar | Director | – |
| Habib J. Dable | Director | – |
| Linda A. Hill | Director | – |
| Lonnel Coats | Director | – |
| Douglas S. Ingram | Director | 25,000 |
| Sekar Kathiresan | Director | – |
| Jami Rubin | Director | 67,242 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Patel | $4.65M | $9.12M | $1.60M | $20 | $120 |
| FY2024 Dr. Patel | $13.08M | -$1.28M | $5.09M | $10 | $91 |
| FY2023 Dr. Patel | $19.77M | $5.29M | $6.27M | $26 | $92 |
| FY2022 Dr. Patel | $8.12M | -$5.23M | $2.78M | $36 | $89 |
| FY2021 Dr. Patel | $8.53M | -$3.35M | $2.26M | $74 | $99 |
| FY2020 Dr. Patel | $3.58M | $62.93M | $952.65K | $119 | $107 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 192 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 13, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |